Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2000

View Archived Issues

Aquila receives SBIR grant to use CD1 technology in pursuit of Chlamydia vaccine

Atrix and Elan form partnership focused on oncology and pain management

Interim results indicate that Remune + antiviral drugs may stimulate killer T-cell activity

Panacea enters agreements with Loyola covering Lewy body disorders

BioSante signs option license agreement with ID Biomedical for vaccine delivery

First selective, irreversible N-SMase inhibitor designed by German university researchers

NitroMed and UT report phase II results of NMI-870 as treatment for female sexual dysfunction

Access to commence phase III clinical trials with OraDisc

Development of CI-1033, an irreversible inhibitor of EGF tyrosine kinase activity

CEP-1347 characterized at medicinal chemistry meeting as potential antiparkinsonian

PTK-787/ZK-222584 expected to show improved selectivity as kinase inhibitor, according to SAR

ENDO 2000: focus on cardiovascular effects of examorelin

EB-1089 as a potential agent for the management of refractory thyroid carcinoma

Sch-66336 warrants further evaluation for the treatment of glioblastoma multiforme

Eniporide now claimed to be useful in NIDDM

Lilly claims new uses for LY-203638

Selective PDE4 inhibitors with bronchodilating, antiinflammatory properties

Sanofi-Synthelabo synthesizes new compounds for GABAergic transmission-associated disorders

Dual D2 and 5-HT1A receptor partial agonists claimed for depression and anxiety

Oxazolidinone antibacterial agents from Bayer

More neuraminidase inhibitors in development at Gilead

Korean laboratory presents new and improved proton pump inhibitors

New Merck compounds selectively antagonize alpha1A-adrenoceptors

SC-744 and its active enantiomer SC-795, two new CETP inhibitors

Advantage-S study fails to demonstrate effectiveness as HIV prophylactic

Aventis receives E.U. approval for Lantus

Nutropin Depot now available

Elan receives FDA approvable letter for ziconotide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...